Events2Join

FDA Approves New Weight Loss Drug


FDA Approves New Medication for Chronic Weight Management

Tirzepatide, the active ingredient in Zepbound, is already approved under the trade name Mounjaro to be used along with diet and exercise to ...

FDA Approves First Treatment to Reduce Risk of Serious Heart ...

The FDA approved a new use for a drug to reduce the risk of ... “Wegovy is now the first weight loss medication to also be approved ...

FDA approves new weight loss drug with remarkable track record

It's the kind of weight loss you'd expect with some types of bariatric surgery.” Zepbound, medication that mimics two hormones, wins FDA ...

FDA Approves New Drug Treatment for Chronic Weight ...

This under-the-skin injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014.

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight ...

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight ...

The Medical Minute: What to know about Ozempic and weight loss ...

Ozempic, which has become synonymous with weight loss medication, is FDA-approved only for treatment of Type 2 Diabetes Mellitus (T2DM).

FDA approves new version of diabetes drug Mounjaro to be sold for ...

A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.

16 New Weight Loss Drugs - GoodRx

More than ten medications are already FDA approved for weight loss. Wegovy (injectable semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide) are ...

FDA Approves Diabetes Drug Tirzepatide for Chronic Weight ...

Tirzepatide is already approved to treat type 2 diabetes, and is now approved for chronic weight management in adults with obesity or overweight ...

FDA approves weight loss drug from Eli Lilly that helped people lose ...

Zepbound is the latest entrant into the field of powerful new drugs that already includes Novo Nordisk's Ozempic and Wegovy and Lilly's Mounjaro ...

FDA approves weight-loss drug for treatment to reduce cardiac ...

Wegovy (semaglutide) injection, an injectable weight-loss medication, was approved to reduce the risk of cardiovascular events, including heart attack, stroke, ...

A new version of the diabetes drug Mounjaro can be used for weight ...

The US Food and Drug Administration approved Eli Lilly's drug, named Zepbound. The drug, also known as tirzepatide, helped dieters lose as much as 40 to 60 ...

New GLP-1 weight loss drug Zepbound approved by FDA

Eli Lilly's new obesity medication Zepbound (tirzepatide) recently received FDA approval. Experts explain how the GLP-1 drug works and ...

FDA approves new weight loss drug Zepbound - NBC News

The FDA approved a new drug for obesity, Zepbound, made by Eli Lilly, which is potentially more effective at losing weight than any other ...

F.D.A. Approves New Obesity Drug That Will Compete With Wegovy

F.D.A. Approves New Obesity Drug That Will Compete With Wegovy. Zepbound, which is already sold by Eli Lilly as the diabetes treatment Mounjaro, ...

Are the Newest Weight Loss Drugs Too Good to be True? - UCSF

Wegovy is FDA-approved for obesity. Ozempic and Mounjaro are FDA-approved for diabetes. However, the manufacturer of Mounjaro is now seeking FDA approval.

FDA approves a new weight loss drug, Zepbound from Eli Lilly

The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.

FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) ...

FDA approves new weight loss drug - YouTube

Zepbound was approved by the FDA for adults with obesity or those considered overweight with at least one weight-related condition, ...

What to Know About Zepbound, the New Weight Loss Drug

Many people have used Mounjaro off-label to lose weight since it was initially approved in May 2022, but the move could pave the way for ...